Article info
Original research
Moral motivation regarding dementia risk testing among affected persons in Germany and Israel
- Correspondence to Professor Silke Schicktanz, Department for Medical Ethics and History of Medicine, University Medical Center Göttingen, 37073 Gottingen, Niedersachsen, Germany; silke.schicktanz{at}medizin.uni-goettingen.de
Citation
Moral motivation regarding dementia risk testing among affected persons in Germany and Israel
Publication history
- Received October 9, 2020
- Accepted July 2, 2021
- First published July 21, 2021.
Online issue publication
October 31, 2022
Article Versions
- Previous version (21 July 2021).
- Previous version (19 August 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Other content recommended for you
- On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Personal utility in genomic testing: is there such a thing?
- Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population
- CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies
- Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia
- New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist
- CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
- Impact of dementia on informal care: a systematic review of family caregivers’ perceptions
- Resilience of family caregivers of people with dementia in South Korea: protocol for a scoping review
- Destruction of White Matter Integrity in Patients With Mild Cognitive Impairment and Alzheimer Disease